← SynDRA
SELPERCATINIB
SynDRA canonical compound SYN0039920 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | RET |
|---|
| Mechanism of action | ret tyrosine kinase inhibitor |
|---|
| Indication | medullary thyroid cancer (mtc) |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- RET INHIBITOR
- Tyrosine-protein kinase receptor RET inhibitor
- ret tyrosine kinase inhibitor
Drug classes
- Kinase Inhibitor
- P-Glycoprotein Inhibitors
- Cytochrome P450 2C8 Inhibitors
- Breast Cancer Resistance Protein Inhibitors
- Cytochrome P450 3A Inhibitors
- Multidrug and Toxin Extrusion Transporter 1 Inhibitors
- Rearranged during Transfection (RET) Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- retevmo
- LOXO-292
- LY3527723
- Ret inhibitor loxo-292
- LY-3527723
- Retevmo
- Retsevmo
- MFOVQWYFURMVKU-IWAAJCSBSA-N
- LOXO292
- ARRY-192
- LOXO 292
- EX-A2636
- CEGM9YBNGD
- Loxo-292
- WHO 10967
- selpercatinibum
- RefChem:58689
- RET Kinase Inhibitor LOXO-292
- DTXCID001510634
- Selpercatinib (LOXO-292)
- US10112942, Example 166
- Selpercatinib [INN]
- Selpercatinib [USAN]
- Serpercatinib
- Retevmo (TN)
- MFCD31814089
- UNII-CEGM9YBNGD
- Selpercatinib (Standard)
- LOXO-292; Selpercatinib
- Selpercatinib [USAN:INN]
- Selpercatinib(LOXO-292)
- Selpercatinib(LOXO-292)?
- orb1299110
- SCHEMBL20071478
- SCHEMBL29349774
- SCHEMBL29362388
- Selpercatinib (JAN/USAN/INN)
- GTPL10318
Reported adverse events
- Abdominal pain
- Constipation
- Dry mouth
- Electrocardiogram QT prolonged
- Fatigue
- Headache
- Hypersensitivity
- Hypertension
- Hypothyroidism
- Infection
- Lymphocyte count decreased
- Nausea
Look up SELPERCATINIB in the interactive SynDRA portal →